Central Neuromodulators in Irritable Bowel Syndrome: Why, How, and When

Area of Science:

• Neurogastroenterology
• Pharmacology
• Psychiatry

Background:

• Irritable Bowel Syndrome (IBS) is a functional gastrointestinal disorder often managed with central neuromodulators.
• Central neuromodulators influence neurotransmitter systems (serotonin, noradrenaline, dopamine) along the brain-gut axis.
• These agents impact gut motility, visceral sensitivity, and psychiatric comorbidities associated with IBS.

Purpose of the Study:

• To review the role of central neuromodulators in Irritable Bowel Syndrome (IBS) management.
• To guide the selection of appropriate neuromodulators based on predominant IBS symptoms and pharmacological properties.
• To outline treatment duration, augmentation strategies, and tapering protocols for central neuromodulator therapy in IBS.

Main Methods:

• Review of pharmacological properties of central neuromodulators used in IBS.
• Analysis of symptom-based selection criteria for antidepressants (TCAs, SNRIs, SSRIs).
• Discussion of treatment response timelines, relapse prevention, augmentation, and discontinuation strategies.

Main Results:

• Tricyclic antidepressants (TCAs) are first-line for IBS pain; Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs) are alternatives.
• Selective Serotonin Reuptake Inhibitors (SSRIs) help anxiety and constipation but not pain; TCAs help diarrhea but may cause constipation.
• Clinical response takes 6-8 weeks, with 6-12 months of treatment for relapse prevention; augmentation and slow tapering are recommended.

Conclusions:

• Central neuromodulators are effective for IBS, with tailored selection based on symptoms (pain, anxiety, bowel habit) crucial for optimal outcomes.
• Long-term treatment and potential augmentation with atypical antipsychotics or behavioral therapies are important for sustained IBS symptom control.
• Careful, slow tapering of central neuromodulators is necessary to avoid discontinuation effects.